Compare GSK plc (GSK) vs Nasdaq100 ETF (QQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Nasdaq100 ETF — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Nasdaq100 ETF trades at $751.27 (market cap $506.92B). The key difference: Nasdaq100 ETF is far larger — about 5.5× GSK plc's market cap, and GSK plc pays a 3.9% dividend while Nasdaq100 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Nasdaq100 ETF for 162 Days on average.
| GSK | QQQ | |
|---|---|---|
Market Cap | $91.88B | $506.92B |
Volume | 7,730,529 | 48,326,518 |
Sector | Health | — |
52-Week High | $61.18 | $759.66 |
52-Week Low | $43.24 | $558.34 |
Typical Hold Time | 93 Days | 162 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
QQQ trades at $747.64, down 1.33% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The ETF maintains strong institutional interest despite mixed analyst sentiment. Recent news highlights QQQ's concentration in technology stocks and ongoing comparisons with lower-cost alternatives like VOO and QQQM.
The outlook remains positive given QQQ's exposure to leading tech innovators and AI-driven growth potential, though elevated valuations and interest rate sensitivity present near-term risks. Long-term growth prospects appear solid, but investors should monitor concentration risk and fee differentials among competing ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →
